Avalo Therapeutics (AVTX) Projected to Announce Earnings on Thursday

Avalo Therapeutics (NASDAQ:AVTX) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.5946) per share for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Avalo Therapeutics (NASDAQ:AVTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). On average, analysts expect Avalo Therapeutics to post ($2.95) EPS for the current fiscal year and ($2.62) EPS for the next fiscal year.

Avalo Therapeutics Stock Performance

Shares of Avalo Therapeutics stock traded up $0.05 during trading hours on Tuesday, hitting $7.37. The company’s stock had a trading volume of 184,686 shares, compared to its average volume of 1,305,550. The business has a 50 day moving average price of $14.52 and a two-hundred day moving average price of $16.01. Avalo Therapeutics has a 12-month low of $6.53 and a 12-month high of $24.27. The company has a market cap of $395.09 million, a PE ratio of -1.69 and a beta of 0.68.

Insider Activity at Avalo Therapeutics

In other Avalo Therapeutics news, CFO Christopher Sullivan sold 12,394 shares of the stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the completion of the transaction, the chief financial officer owned 39,900 shares of the company’s stock, valued at $651,567. This represents a 23.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 23,258 shares of company stock worth $395,434. 4.46% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on AVTX. Oppenheimer set a $16.00 target price on Avalo Therapeutics in a research report on Monday, October 26th. BTIG Research lowered their price target on Avalo Therapeutics to $10.00 and set a “buy” rating on the stock in a report on Friday, October 23rd. Guggenheim downgraded Avalo Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, October 23rd. HC Wainwright lowered shares of Avalo Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, October 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a report on Wednesday, September 16th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.00.

About Avalo Therapeutics

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.